Ind Swift Laboratories Ltd has achieved the Therapeutic Goods Administration (TGA) certification from the Australian Common Wealth Department of Health and Ageing for its manufacturing Facility for the 1.18 billion drug 'Clarithromycin'. The company is one of the largest manufacturer of Clarithromycin in the world and enjoys 30-33% of the World Capacities for this drug, claims a release.

According to the company release, the manufacturing facilities situated at Derabassi Punjab are one of the key and biggest manufacturing facilities of the company. The facility has eight dedicated blocks to manufacture high class API and advanced intermediates for the regulated markets. The company's another facility is situated in tax exempted zone of Jammu (J&K) which is primarily focused on manufacturing of API for the Domestic clients.

"It is a significant achievement as the Company is focusing on the Regulated markets for its growth and the TGA certification will leverage the Company's intrinsic potential and place it at par with the other leading players in the industry," said. V K Mehta Jt. Managing Director.

The company has filed 7 DMFs in US and several DMFs with the European authorities for its active pharmaceutical ingredients. The company has recently launched four new APIs these are Letrozole (Aromtase Inhibitor), Quetiapine Fumerate (Anti-Psychotic), Aripiprazole (Anti-Pshycotic) & Ropinirole (Parkinson Disease).